SAN DIEGO, Aug. 25, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with Inflammatory

-Prometheus to receive an upfront payment and payments upon achievement of several milestones expected within the next 12 months– -Falk to pay 25% of global development costs of IBD program- -Falk to leverage the Prometheus 360™ platform to create next-generation IBD precision medicines- SAN DIEGO

SAN DIEGO, August 4, 2020 / PRNewswire / — Prometheus Biosciences, Inc., (“Prometheus”) a biopharmaceutical company committed to the discovery, development, and commercialization of a broad portfolio of novel precision therapeutics and companion diagnostics for patients living with Inflammatory

Company Plans to Complete Series C Financing in Fourth Quarter of 2019, Followed by Initial Public Offering for 2020   SAN DIEGO, Sept. 5, 2019 /PRNewswire/ — Precision IBD, Inc., a biopharmaceutical company focused on the discovery and development of a broad portfolio of precision therapeutics and